Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Custom Media Event: ESG Summit
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Transformation Summit
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain Revenue Cycle
    • - Hospital at Home
    • - Workplace of the Future
    • - Virtual Health
    • - Future of Healthcare Staffing
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
August 07, 2014 01:00 AM

How to hasten Ebola drug testing, and maybe save lives

Merrill Goozner, Editor
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Goozner

    It won't be long before more sick medical aid workers, not to mention West African nations in the grip of the Ebola outbreak, begin demanding access to the experimental immune therapy under development by a West Coast biotechnology firm.

    Rather than just saying no, as some bioethicists and defenders of the Food and Drug Administration regulatory process have urged, regulators will hopefully recall their own history, which shows how to make experimental therapies available to dying patients without undermining either future studies or the regulatory process.

    That history comes in part from the early days of HIV/AIDS drug development, when dying patients, mostly young, articulate homosexuals, demanded access to experimental therapies. The FDA created a compassionate-use program that enabled companies to provide the drugs they had in development outside their ongoing clinical trials.

    San Diego-based Mapp Biopharmaceutical's experimental Ebola drug, a combination of monoclonal antibodies whose development has been completely financed by the U.S. government, hasn't even reached the stage where it can be tested in humans. Such trials first require successful safety testing in animals before the FDA will approve safety testing in healthy people.

    Only after it passes that test can human clinical trials begin under the usual FDA procedures. But what would be the shape of an Ebola clinical trial? Double-blind, randomized trials—the gold standard for regulators—are out of the question. Can you imagine anyone dying from Ebola volunteering for a trial where one group received a placebo?

    The current outbreak has created a situation where compassionate-use policy isn't relevant. There is no drug and there are no trials. Companies with biotech capabilities are gearing up to manufacture the experimental compound, a very difficult process as Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, told CNN earlier this week. But once it arrives, how can it be distributed without undermining future research designed to learn if it actually works?

    Here's where the FDA should take a second page from its history. In the 1960s, more than half of children stricken with various forms of cancer died from the disease as oncologists floundered through the existing armamentarium looking for useful drug combinations.

    But rather than celebrating each survival miracle, while having no sense of what happened to the larger group, every child given a set of drugs or procedures was enrolled in a clinical trial. The protocols and outcomes data were rigorously collected and recorded. Over time, protocols were adjusted to reflect the best outcomes. Today, because of those adjustments and the arrival of new medicines and procedures that were fed into the system, over 90% of children stricken with cancer survive until adulthood.

    The experimental Ebola therapy could be treated the same way. Its developers already have two data points for its first-stage safety trial—the two western aid workers who received the drugs.

    As more of the drug gets manufactured, the FDA and the World Health Organization could sanction its use in West Africa, as long as health authorities and patients there give informed consent that they are aware of the risks and understand that it might not work. While there's a history of western drug companies violating informed consent rules while testing medicines in Africa, in today's environment, with nearly 1,000 dead and millions more living in fear, it's unlikely that such consent will be hard to obtain.

    To ease the way, and more importantly, to further science, health authorities should tell every patient that he or she will be enrolled in a massive, real-time clinical trial where medical authorities will track the results of what is likely to be an unprecedented human experiment.

    Follow Merrill Goozner on Twitter: @MHgoozner

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    medicare and money
    Inspector General pushes CMS to recover $226M in Medicare overpayments
    Ezike 800.jpg
    Former Illinois health chief Ezike under scrutiny by state's top ethics investigator
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Transformation Summit
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain Revenue Cycle
        • - Hospital at Home
        • - Workplace of the Future
        • - Virtual Health
        • - Future of Healthcare Staffing
      • Custom Media Event: ESG Summit
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing